Similar articles

• The role of Sandostatin in acromegaly.

  Sassolas G. Sassolas G. Metabolism. 1992 Sep;41(9 Suppl 2):39-43. doi: 10.1016/0026-0495(92)90029-a. Metabolism. 1992. PMID: 1518432 Review.
• Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.

  Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T. Haraguchi K, et al. Endocr J. 1995 Apr;42(2):295-300. doi: 10.1507/endocrj.42.295. Endocr J. 1995. PMID: 7627275
• Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).

  Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG. Warnet A, et al. Acta Endocrinol (Copenh). 1991 Apr;124(4):487-91. doi: 10.1530/acta.0.1240487. Acta Endocrinol (Copenh). 1991. PMID: 2031445
• [A case of thyrotropin-, growth hormone-, and prolactin-secreting pituitary adenoma with a remarkable response to long-acting somatostatin analogue (SMS201-995)].

  Usui T, Sako Y, Matsumoto M, Kita T, Shimatsu A, Imura H. Usui T, et al. Nihon Naika Gakkai Zasshi. 1989 Nov;78(11):1605-6. doi: 10.2169/naika.78.1605. Nihon Naika Gakkai Zasshi. 1989. PMID: 2614206 Japanese. No abstract available.
• Somatostatin analogues in pituitary adenomas.

  von Werder K. von Werder K. Recent Results Cancer Res. 1993;129:25-44. doi: 10.1007/978-3-642-84956-5_2. Recent Results Cancer Res. 1993. PMID: 8394595 Review. No abstract available.